Adis JournalsBrowse
Summary Slide.png (117.85 kB)
Download file

Ubrogepant for the Acute Treatment of Migraine: Pooled Efficacy, Safety, and Tolerability From ACHIEVE I and ACHIEVE II Phase 3 Randomized Trials

Download (117.85 kB)
figure
posted on 2021-02-15, 14:18 authored by Adis journals on behalf of, Susan Hutchinson, David W. Dodick, Christina Treppendahl, Nathan L. Bennett, Sung Yun Yu, Hua Guo, Joel M. Trugman
Article full text

The above summary slide represents the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, please see the full text online (see “read the peer-reviewed publication” opposite).
© The authors, CC-BY-NC 2021.

History

References

Usage metrics

Read the peer-reviewed publication

Ubrogepant for the Acute Treatment of Migraine: Pooled Efficacy, Safety, and Tolerability From ACHIEVE I and ACHIEVE II Phase 3 Randomized Trials
Neurology and TherapyNeurology and Therapy

Categories

Keywords

Calcitonin gene‒related peptideGepantHeadacheMigraineUbrogepant

Licence

CC BY-NC 4.0

Exports